According to filings with the U.S. Securities and Exchange Commission, Syntax Bio has raised $14,400,000.00 in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansueto Office, Portal Innovations, Draper Associates, Allegis Capital, LongGame, Mayo Clinic, the Illinois Department of Commerce and Economic Opportunity, Illinois Ventures, Exit Fund, Sigma Group, and Walder Ventures.

About Syntax Bio
Syntax Bio is a synthetic biology company programming the next generation of cell therapies. Its proprietary Cellgorithm platform uses a CRISPR-based system to program and accelerate stem cell differentiation, transforming how regenerative medicines are discovered, developed, and manufactured. By replacing slow, labor-intensive differentiation processes with a rapid, programmable approach that mimics human development, Syntax Bio makes cellular generation more reliable and scalable at unprecedented speed, unlocking new possibilities across the biotechnology industry.

To learn more, visit https://www.syntax-bio.com/
Linkedin: https://www.linkedin.com/company/syntax-bio/

Contact:
John Craighead, Chief Executive Officer
https://www.linkedin.com/in/biotechanalyst/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.